Biotech Values

[randychub]

Thanks Poorgrad. That is pretty good data. To bad it did not pan out it would have been nice for those patients.

I guess I fell more confident with tesmilifene because of the number of patients in the first phase 3 trial but I guess you never know what will happen until trials are completed and the FDA gives the final OK.


In the first phase 3 trial for tesmilifene there was 305 patients overall 152 in one arm, 153 in the other arm, which showed a survival benefit of 50%.

There where 191 patients with aggressive breast cancer in the trial (those with mets within 36 months of initial diagnosis). This is the only group being recruited in the 2nd phase 3 trial. In this group the overall survival benefit was 143%.


Randy